secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tectonic Therapeutic, Inc. (TECX)
CIK:        0001681087
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001140361-22-040396
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AVROBIO Q3 net loss narrows to $23M; cash runway into Q1 2024; Gaucher update Dec. 7
--------------------------------------------------------------------------------

- Net loss of $23.0M vs $32.6M in Q3 2021; R&D expenses fell to $15.9M from $23.0M.
- Cash and equivalents $116.0M as of Sept. 30, 2022, expected to fund operations into Q1 2024.
- Received rare pediatric disease designation for AVR-RD-02 (Gaucher) and AVR-RD-04 (cystinosis) from FDA.
- Patient dosing completed in collaborator-sponsored Phase 1/2 cystinosis trial; interim data show systemic effect.
- Investor update on Gaucher disease program scheduled for Dec. 7, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681087/000114036122040396/0001140361-22-040396-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681087/000114036122040396/ny20005640x2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-040396

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer